| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
MID-1 targets the interaction between MG53 (Mitsugumin 53) and insulin receptor substrate-1 (IRS-1). MG53 is a protein that promotes the ubiquitination and degradation of IRS-1, a key adaptor protein in insulin signaling. By disrupting the MG53-IRS-1 interaction, MID-1 prevents IRS-1 degradation, thereby increasing IRS-1 levels and enhancing insulin signaling and glucose uptake.
|
|---|---|
| ln Vitro |
MID-1 (5 μM; 24 h) breaks the MG53-IRS-1 interaction, which raises the level of IRS-1 expression in skeletal muscle[1]. When NLUC-IRS-1 and CLUC-C14A are expressed in HEK 293 cells, MID-1 (10 μM; 12 h) decreases the luciferase activity[1]. In HEK 293 cells, MID-1 (1–20 μM; 12 h) interferes with the MG53–IRS-1 interaction but not the MG53–FAK interaction[1]. In HEK 293 cells, MID-1 (0.1-10 μM; 4-24 h) eliminates MG53-induced IRS-1 ubiquitination and degradation[1]. In C2C12 myotubes, MID-1 (5–10 μM; 24 h) boosts insulin signaling and insulin-elicited glucose uptake[1]. Enhances skeletal myogenesis (5–10 μM; 24 h)[1].
In vitro, MID-1 has been shown to disrupt the MG53-IRS-1 interaction and abolish MG53-induced IRS-1 ubiquitination and degradation. Its activity is typically assessed using cell-based assays that measure IRS-1 protein levels, ubiquitination, and downstream insulin signaling events, such as Akt phosphorylation and glucose uptake. |
| ln Vivo |
In vivo MID-1 pharmacokinetics are not good[1].
In vivo, MID-1 has been studied in animal models of insulin resistance and diabetes. By disrupting the MG53-IRS-1 interaction, it increases IRS-1 expression and enhances insulin signaling in skeletal muscle, leading to improved glucose uptake and glycemic control. These studies suggest its potential as a therapeutic agent for metabolic disorders. |
| Enzyme Assay |
Cell-free assays for MID-1 typically involve measuring its ability to disrupt the MG53-IRS-1 interaction using surface plasmon resonance (SPR) or co-immunoprecipitation assays. These assays are used to characterize the compound's potency in inhibiting the protein-protein interaction.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: C2C12 myotubes Tested Concentrations: 5 μM Incubation Duration: 24 h Experimental Results: Increased the IRS-1 protein level. In vitro cellular assays are conducted to evaluate the functional activity of MID-1. Muscle cells or other cell types expressing MG53 and IRS-1 are treated with the compound. IRS-1 protein levels, ubiquitination, and downstream insulin signaling events, such as Akt phosphorylation and glucose uptake, are measured. These assays confirm that MID-1 effectively disrupts the MG53-IRS-1 interaction and enhances insulin signaling. |
| Animal Protocol |
In vivo animal experiments typically involve rodent models of insulin resistance or type 2 diabetes. Animals are administered MID-1. Insulin sensitivity and glucose tolerance are assessed. IRS-1 expression levels and insulin signaling in skeletal muscle are measured to confirm target engagement.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of MID-1 are typical of a small molecule inhibitor. Its molecular formula is C12H11N3O4S. While detailed PK parameters are not widely published, its properties suggest it is designed to have favorable drug-like characteristics, including good permeability and metabolic stability, to support efficacy in vivo.
|
| Toxicity/Toxicokinetics |
The toxicity profile of MID-1 is not extensively documented but is likely to be similar to other small molecule inhibitors. Common adverse effects may include gastrointestinal disturbances. Preclinical studies would typically involve acute and chronic dosing in animal models to assess safety margins and identify potential target organ toxicities.
|
| References | |
| Additional Infomation |
MID-1 is a research compound that disrupts the MG53-IRS-1 interaction, leading to increased IRS-1 expression and enhanced insulin signaling. It is being studied for its potential to treat insulin resistance and type 2 diabetes. The compound is a valuable tool for studying the role of MG53 in insulin signaling and for developing new therapeutic strategies for metabolic disorders.
|
| Molecular Formula |
C12H11N3O4S
|
|---|---|
| Molecular Weight |
293.298441171646
|
| Exact Mass |
293.047
|
| CAS # |
312608-54-1
|
| PubChem CID |
2858708
|
| Appearance |
Orange to red solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C(=CN=C1NC(C1C=CC(=CC=1)OCC)=O)[N+](=O)[O-]
|
| InChi Key |
LMDLIMGAGZHZSR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H11N3O4S/c1-2-19-9-5-3-8(4-6-9)11(16)14-12-13-7-10(20-12)15(17)18/h3-7H,2H2,1H3,(H,13,14,16)
|
| Chemical Name |
4-ethoxy-N-(5-nitro-1,3-thiazol-2-yl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 31.25 mg/mL (106.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (7.09 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4095 mL | 17.0474 mL | 34.0948 mL | |
| 5 mM | 0.6819 mL | 3.4095 mL | 6.8190 mL | |
| 10 mM | 0.3409 mL | 1.7047 mL | 3.4095 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
